Tuesday tips round-up: Stobart, Vectura, Mitie
24th May 2011 06:25
Yesterday, the logistics group Stobart issued full-year figures, with pre-tax profits falling short of market hopes. But the share price rose as the focus turned to the confident outlook statement. Moreover, the stock is down more than 20% since the recent February peak. That, unsurprisingly, has hi
Read moreVectura losses narrow
23rd May 2011 08:36
Vectura, the respiratory inhaler firm, reduced losses for the year, drove revenues higher and said it is on track for annual cost-savings of approximately £6m. Loss after tax reduced to £8.8m for the year ended 31 March 2011 from a loss of £10.2m in 2010. Revenue increased to £42.9m from £40.1m.
Read moreLondon close: Battering for miners and banks
16th Nov 2010 17:08
It was downhill almost all the way for Footsie in the afternoon session after the US opened sharply lower, with miners getting a real bashing on the prospect of a slow-down in the Chinese economy. No less an authority than star fund manager Anthony Bolton raised the prospect today, in the first set
Read moreSector movers: Vectura lifts pharma stocks after study
16th Nov 2010 14:17
Respiratory inhaler developer Vectura is among the stocks lifting the pharmaceutical sector after positive data from a Phase II clinical study of a treatment for Parkinson's disease. Vectura said the results of its study show that the Parkinson's treatment VR040 improves the control of movement in
Read moreLondon afternoon: Gloomy miners
16th Nov 2010 14:10
Footsie retreated further over the lunch time session with mining stocks largely responsible for the decline, as metal prices pull back on fears that China will act to cool down its economy in the interests of reining in inflation. Antofagasta, Kazakhymys, Fresnillo, Xstrata and Rio Tinto are t
Read moreParkinson's treatment results boost Vectura
16th Nov 2010 13:50
Shares in Vectura moved higher after the respiratory inhaler developer announced higher revenues, sharply narrower losses and positive data from a Phase II clinical study of a treatment for Parkinson's disease. Vectura said the results of its study show that the Parkinson's treatment VR040 improves
Read moreTechMARK movers: Vectura data boost
16th Nov 2010 13:29
Positive phase II data for its Parkinson's disease treatment has pushed up shares in Vectura. The VR040 treatment shows positive outcomes on the ability to control movement. This will help Vectura to licence the drug before phase II studies commence. Figures for the six months to September 2010
Read moreTechMARK movers: Xaar continues rise
22nd Oct 2010 13:44
Print heads developer Xaar continues to rise after yesterday's positive trading statement and fundraising. The shares are trading at a 32% premium to the 170p a share at which Xaar is raising £15m to expand production capacity. The share price has risen by one-quarter this week. Ink jet printer
Read moreSmall caps: Argos/Rockhopper, Kedco, STV...
21st Oct 2010 16:08
Argos Resources and Rockhopper Exploration have both signed contracts for a seismic survey of their prospect in the Falklands Basin with Polarcus, the marine geophysical company. The oil and gas exploration groups will acquire a 3D seismic survey over their respective locations, as well as adjacent
Read moreTechMARK movers: Vectura deal
6th Aug 2010 14:20
GlaxoSmithKline has signed a worldwide non-exclusive deal with Vectura worth £20m in up front and milestone payments. GSK wants to use some of Vectura's dry powder drug formulation patents in its own respiratory products. The initial payment of £10m is due in September. There are also potential an
Read moreSmall caps round-up: Vectura, Norseman, Sabien
6th Aug 2010 11:16
Vectura is at its highest since mid- March after GlaxoSmithKline agreed a £20m deal to license some of the inhaled therapies developer's formulation patents. Glaxo will pay Vectura £10m in September and £10m by the time two of the compounds are launched. It will also receive royalties worth up to £
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
2nd Aug 2010 14:21
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1321 GMT [Dow Jones] Ambrian initiates coverage of Vectura Group (VEC.LN) with a buy rating and fair value of 98p. Analyst Ch
Read moreMARKET TALK: Ambrian Starts Drug Maker Vectura At Buy
2nd Aug 2010 14:21
1321 GMT [Dow Jones] Ambrian initiates coverage of Vectura Group (VEC.LN) with a buy rating and fair value of 98p. Analyst Chris Redhead says the drug maker is significantly undervalued. A program with Novartis (NOVN.VX) could bring the companies a significant share of the $9 billion-a-year market f
Read moreWetherspoon chief exec sells
14th Jun 2010 16:36
John Hutson, the chief executive of pub operator JD Wetherspoon, has sold nearly one-third of his shareholding in the company. Hutson sold 30,000 shares at 429p each, which leaves him with 61,628 shares. This is the second sale in less than three months. He sold 20,000 shares at 516.8p a share e
Read moreUK SMALLCAP ROUNDUP: Egdon Resources Up On Production Boost
14th Jun 2010 16:00
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps EGDON RESOURCES PLC (EDR.LN), an oil and gas company, Monday said it intends to revive plans to generate electricity from gas produced from its Keddingto
Read more